A new way for our members to access the huge wealth of knowledge content ICE has. Organised into bite-sized modules.
Our learning is structured around these key areas:
Courses, workshops and membership surgeries to help you achieve professional qualification.
Access videos covering key areas of professional qualification.
Courses, help and advice to advance your career no matter what stage you are at.
Specialist training courses let you learn new skills and add to your personal development.
Earn new qualifications to boost your career and demonstrate your abilities.
The Clinical Biomanufacturing Facility (CBF) at the University of Oxford (UK) produced the first clinical batches of the ChAdOx1 nCoV-19 vaccine against SARS-coV-2 in April 2020. In collaboration with our industrial partner AstraZeneca we have moved rapidly to get the vaccine into phase III clinical trials across the globe, and interim analysis has shown good safety and efficacy, leading to its licensure in the UK and around the world.
We developed and optimised a route to scaled up manufacture in order to produce millions of doses in the hope that it (in conjunction with other vaccines) will deliver an effective route to end the current pandemic. I will present the efforts that underpinned this highly rapid development of a vaccine against a previously unknown pathogen, the lessons that we have learnt, as well as the results generated from our early phase trials.
Catherine Green is an Associate Professor in the Nuffield Department of Medicine, Oxford and the Monsanto Senior Research Fellow at Exeter College, Oxford. She also heads the Clinical BioManufacturing Facility (CBF).
Cath graduated from Churchill College, Cambridge and did her PhD at the Cancer Research UK Clare Hall Laboratories. After postdoctoral work at the Institut Curie in Paris, and at the University of Sussex, she returned to Cambridge to set up a group in the Department of Zoology, studying DNA replication. She moved to Oxford in 2012 to head a research team and core facility at the Wellcome Centre for Human Genetics, with a focus on Chromosome Dynamics. In 2018 she also became head of the Clinical BioManufacturing Facility.
The CBF has, in collaboration with scientists at the Jenner Institute, over the last 15 years made many novel vaccines for clinical trials, covering diseases including malaria, TB, influenza, MERS, Zika, rabies and Ebola (among others). Cath’s team has been an integral part of the University's project to develop a vaccine against the SARS-CoV-2 virus that causes COVID-19, in record time. The CBF made the first batch of clinical material that has been used in Oxford's COVID-19 vaccine trials and continues to support these trials.
e: [email protected]